CDKN2A and glioblastoma: Cellular senescence was not addressed in these studies but in the light of our results using the p16-3MR transgene, some of the cells targeted by this approach may be malignant senescent cells, extending the notion of detrimental senescent cells to distinct GBM subtypes in agreement with the senescence score analysis performed on data from patient GBMs (Fig. 7).